Limits...
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.

Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T, O'Brien TJ - Br. J. Cancer (2005)

Bottom Line: Tumour-associated differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-SP1) is a novel member of the transmembrane serine proteases.TADG-15 expression was significantly more common in patients with early stage disease compared with patients with advanced stage diseases (namely, stage I, 24 out of 33: 72.7%; stage II/III/IV, 26 out of 56: 46.4%; P=0.0157).The mean value of relative TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053).

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Japan.

ABSTRACT
Tumour-associated differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-SP1) is a novel member of the transmembrane serine proteases. Previous studies indicated that TADG-15 is overexpressed in ovarian tumours; however, relationships between expression of TADG-15 and clinical characteristics of ovarian cancer remain unclear. The purpose of this study was to examine TADG-15 expression in ovarian cancers and determine any associations with clinicopathological characteristics or patient survival. Immunohistochemical study revealed that TADG-15 was expressed in 50 (56.2%) of 89 ovarian carcinomas, whereas it was not detected in normal ovaries. TADG-15 expression was significantly more common in patients with early stage disease compared with patients with advanced stage diseases (namely, stage I, 24 out of 33: 72.7%; stage II/III/IV, 26 out of 56: 46.4%; P=0.0157). Kaplan-Meier survival curves demonstrated that patients with TADG-15-positive tumours have had substantially longer survival (P=0.0480). The mean value of relative TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053). Increased expression of TADG-15 is frequently detected in early stage cancers, with expression level downregulated during progression of disease. TADG-15 is associated with early stage ovarian cancer and longer patient survival; therefore, it may be a favourable prognostic marker for this malignancy.

Show MeSH

Related in: MedlinePlus

Semiquantitative PCR analysis of TADG-15 expression. Expression levels of TADG-15 relative to β-tubulin are significantly elevated in carcinomas compared with levels in normal ovaries.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2361855&req=5

fig3: Semiquantitative PCR analysis of TADG-15 expression. Expression levels of TADG-15 relative to β-tubulin are significantly elevated in carcinomas compared with levels in normal ovaries.

Mentions: In order to evaluate mRNA expression of TADG-15 in ovarian carcinomas, we performed semiquantitative PCR. In a preliminary study, the linearity of PCR amplification was confirmed. Figure 3 shows an example of semiquantitative PCR using TADG-15 primers coamplified with the internal control (β-tubulin) primers. Analysis of data as measured using the densitograph system and compared as ratios of expression (TADG-15/β-tubulin) indicated that TADG-15 expression was significantly elevated in carcinomas compared with that of normal ovaries (P<0.0001) (Table 3). For individual clinical stages of tumours, the mean value of relative TADG-15 mRNA expression ratio was 1.98±0.57 (mean±s.d.) for stage I tumours, 1.37±0.08 for stage II tumours, 1.64±0.34 for stage III tumours, and 1.69±0.31 for stage IV tumours, respectively. The TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053) (Table 3).


Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.

Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T, O'Brien TJ - Br. J. Cancer (2005)

Semiquantitative PCR analysis of TADG-15 expression. Expression levels of TADG-15 relative to β-tubulin are significantly elevated in carcinomas compared with levels in normal ovaries.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2361855&req=5

fig3: Semiquantitative PCR analysis of TADG-15 expression. Expression levels of TADG-15 relative to β-tubulin are significantly elevated in carcinomas compared with levels in normal ovaries.
Mentions: In order to evaluate mRNA expression of TADG-15 in ovarian carcinomas, we performed semiquantitative PCR. In a preliminary study, the linearity of PCR amplification was confirmed. Figure 3 shows an example of semiquantitative PCR using TADG-15 primers coamplified with the internal control (β-tubulin) primers. Analysis of data as measured using the densitograph system and compared as ratios of expression (TADG-15/β-tubulin) indicated that TADG-15 expression was significantly elevated in carcinomas compared with that of normal ovaries (P<0.0001) (Table 3). For individual clinical stages of tumours, the mean value of relative TADG-15 mRNA expression ratio was 1.98±0.57 (mean±s.d.) for stage I tumours, 1.37±0.08 for stage II tumours, 1.64±0.34 for stage III tumours, and 1.69±0.31 for stage IV tumours, respectively. The TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053) (Table 3).

Bottom Line: Tumour-associated differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-SP1) is a novel member of the transmembrane serine proteases.TADG-15 expression was significantly more common in patients with early stage disease compared with patients with advanced stage diseases (namely, stage I, 24 out of 33: 72.7%; stage II/III/IV, 26 out of 56: 46.4%; P=0.0157).The mean value of relative TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053).

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Japan.

ABSTRACT
Tumour-associated differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-SP1) is a novel member of the transmembrane serine proteases. Previous studies indicated that TADG-15 is overexpressed in ovarian tumours; however, relationships between expression of TADG-15 and clinical characteristics of ovarian cancer remain unclear. The purpose of this study was to examine TADG-15 expression in ovarian cancers and determine any associations with clinicopathological characteristics or patient survival. Immunohistochemical study revealed that TADG-15 was expressed in 50 (56.2%) of 89 ovarian carcinomas, whereas it was not detected in normal ovaries. TADG-15 expression was significantly more common in patients with early stage disease compared with patients with advanced stage diseases (namely, stage I, 24 out of 33: 72.7%; stage II/III/IV, 26 out of 56: 46.4%; P=0.0157). Kaplan-Meier survival curves demonstrated that patients with TADG-15-positive tumours have had substantially longer survival (P=0.0480). The mean value of relative TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053). Increased expression of TADG-15 is frequently detected in early stage cancers, with expression level downregulated during progression of disease. TADG-15 is associated with early stage ovarian cancer and longer patient survival; therefore, it may be a favourable prognostic marker for this malignancy.

Show MeSH
Related in: MedlinePlus